Table 1.
Patient characteristics by CR Indicator at 1 year
| Factor | All patients | Less than CR within first year | CR within first year | P-value | Percent of patients w/ data |
|---|---|---|---|---|---|
| Age at registration> = 65 yr | 258/3867 (7%) | 194/2906 (7%) | 64/961 (7%) | 0.986 | 258/3867 (7%) |
| IgA | 735/3086 (24%) | 499/2326 (21%) | 236/760 (31%) | < 0.001 | 735/3086 (24%) |
| IgG | 1868/3086 (61%) | 1549/2326 (67%) | 319/760 (42%) | < 0.001 | 1868/3086 (61%) |
| Female | 1380/3286 (42%) | 1018/2442 (42%) | 362/844 (43%) | 0.542 | 1380/3286 (42%) |
| Albumin < 3.5 g/dL | 1041/3443 (30%) | 819/2590 (32%) | 222/853 (26%) | 0.002 | 1041/3443 (30%) |
| B2M > = 3.5 mg/L | 1517/3681 (41%) | 1126/2753 (41%) | 391/928 (42%) | 0.510 | 1517/3681 (41%) |
| B2M > 5.5 mg/L | 708/3681 (19%) | 517/2753 (19%) | 191/928 (21%) | 0.231 | 708/3681 (19%) |
| Creatinine > = 2 mg/dL | 397/3802 (10%) | 282/2852 (10%) | 115/950 (12%) | 0.056 | 397/3802 (10%) |
| HGB < 10 g/dL | 1280/3785 (34%) | 973/2842 (34%) | 307/943 (33%) | 0.343 | 1280/3785 (34%) |
| LDH > Upper Limit Normal | 403/2244 (18%) | 288/1740 (17%) | 115/504 (23%) | 0.002 | 403/2244 (18%) |
| Platelet Count < 150 × 10^9/L | 635/3758 (17%) | 454/2838 (16%) | 181/920 (20%) | 0.011 | 635/3758 (17%) |
| Any clonal abnormality by cytogenetics | 322/1256 (26%) | 209/822 (25%) | 113/434 (26%) | 0.814 | 322/1256 (26%) |
| BMPC > = 30% | 1986/3077 (65%) | 1472/2260 (65%) | 514/817 (63%) | 0.257 | 1986/3077 (65%) |
| ISS Stage 1 | 1860/2645 (70%) | 1351/1949 (69%) | 509/696 (73%) | 0.057 | 1860/2645 (70%) |
| ISS Stage 2 | 1505/3302 (46%) | 1121/2475 (45%) | 384/827 (46%) | 0.569 | 1505/3302 (46%) |
| ISS Stage 3 | 1242/3388 (37%) | 954/2542 (38%) | 288/846 (34%) | 0.067 | 1242/3388 (37%) |
n/N (%): n—Number with factor, N—Number with valid data for factor
ND No valid observations for factor
*P-value from Fisher’s exact test, otherwise chi-squared test. P-values represent a comparison between groups, not against the overall population